Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.

Nature·2025
Same author

IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor Cells.

Cancer immunology research·2025
Same author

An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV.

Emerging microbes & infections·2023
Same author

Mesenchymal and induced pluripotent stem cell-based therapeutics: a comparison.

Applied microbiology and biotechnology·2023
Same author

Antibodies as drugs-a Keystone Symposia report.

Annals of the New York Academy of Sciences·2022
Same author

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2022

Related Experiment Video

Updated: Jan 17, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgG.

Kevin C Hart1, Paul R Hinton1, Marigold Manlusoc1

  • 1IGM Biosciences Inc., 325 E Middlefield Rd., Mountain View, CA.

Experimental Hematology
|September 16, 2025
PubMed
Summary

An anti-CD20 IgM antibody demonstrates superior complement-dependent cytotoxicity (CDC) compared to IgG antibodies for B-cell lymphoma treatment. This IgM antibody offers enhanced efficacy against resistant cancer cells, suggesting a promising therapeutic alternative.

More Related Videos

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.6K
Real-time Cytotoxicity Assays in Human Whole Blood
08:27

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

12.7K

Related Experiment Videos

Last Updated: Jan 17, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.6K
Real-time Cytotoxicity Assays in Human Whole Blood
08:27

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

12.7K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Complement-dependent cytotoxicity (CDC) is a key mechanism for anti-CD20 IgG antibodies like rituximab in treating B-cell lymphoma.
  • Therapeutic resistance to existing anti-CD20 IgG antibodies necessitates the development of novel treatment strategies.
  • Understanding alternative antibody formats, such as IgM, is crucial for overcoming treatment limitations.

Purpose of the Study:

  • To compare the CDC activity of an anti-CD20 IgM antibody with that of an anti-CD20 IgG antibody.
  • To evaluate the efficacy of anti-CD20 IgM in overcoming resistance mechanisms in B-cell lymphoma.
  • To assess the potential of anti-CD20 IgM as a superior therapeutic option.

Main Methods:

  • Real-time measurement of CDC activity using live-cell imaging and kinetic analysis.
  • Comparative analysis of anti-CD20 IgM and IgG antibodies against target B-cells.
  • Evaluation of antibody efficacy under varying conditions, including low antigen density, low complement levels, and high complement inhibitor expression.
  • Assessment of CDC activity against ex vivo tumor samples from B-cell lymphoma patients.

Main Results:

  • The anti-CD20 IgM antibody exhibited significantly more potent and faster target cell killing via CDC compared to the anti-CD20 IgG antibody.
  • IgM demonstrated enhanced efficacy in eliminating target cells with low CD20 antigen density.
  • The IgM antibody was more effective in low complement concentrations and in the presence of high complement inhibitor expression.
  • Superior CDC activity was observed with the anti-CD20 IgM against patient-derived ex vivo lymphoma samples.

Conclusions:

  • Anti-CD20 IgM antibodies possess superior CDC activity compared to conventional anti-CD20 IgG antibodies in preclinical models.
  • Anti-CD20 IgM shows potential for overcoming resistance mechanisms observed with current IgG-based therapies.
  • These findings support the development of anti-CD20 IgM-based therapeutics for improved B-cell lymphoma treatment.